Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE: As the distribution of PTCL subtypes differs between...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xiaonan, Song, Yuqin, Huang, Huiqiang, Bai, Bing, Zhang, Huilai, Ke, Xiaoyan, Shi, Yuankai, Zhu, Jun, Lu, Guodong, Liebscher, Stefan, Cai, Chunxiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453867/
https://www.ncbi.nlm.nih.gov/pubmed/30904980
http://dx.doi.org/10.1007/s11523-019-00630-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453867/
https://www.ncbi.nlm.nih.gov/pubmed/30904980
http://dx.doi.org/10.1007/s11523-019-00630-y

Ejemplares similares